Dr. Pappalardi Brigida

Doctor

Contacts

Mail: Brigida.Pappalardi@istitutotumori.mi.it
Tel: 0223902637

Specialty / Department

Radiation oncology

Education

Master's Degree in Medicine and Surgery Polytechnic University of Marche, Ancona, 18/03/2008
Specialization in Radiation Oncology University of Milano-Bicocca, 12/03/2015 (Grade: 70/70 cum laude) Duration: 5 years
Postgraduate Diploma (Academy of Oncological Gynecology, MITO Group): 2019

Professional Experience

Radiation Oncology Resident, San Raffaele Hospital, Radiotherapy Department, 2009-2012;
Radiation Oncology Resident, Fondazione IRCCS National Cancer Institute, Radiotherapy Department, 2013-2015;
Radiation Oncology Consultant, Fondazione IRCCS National Cancer Institute, Radiotherapy Department, 2015-2020;
Second-Level Medical Officer, Fondazione IRCCS National Cancer Institute, Radiotherapy Department, 2020- present

Scientific activities

Partecipation in national and international clinical trials
Publications in scientific journals
Contributions to books and educational texts
Presentations at scientific conferences
Abstract at scientific conferences
Research and development of new radiotherapy techniques

Multidisciplinary Team Membership

Actively participates in meetings of the multidisciplinary team for gynecological pathologies, which includes gynecological surgeons, gynecological oncologists, pathologists, nuclear medicine physicians, and radiologists, to identify the best therapeutic pathway for the patient.

Ionizing radiations increase the activity of the cell surface glycohydrolases and the plasma membrane ceramide content. Authors: M. Aureli, R. Bassi, A. Prinetti, E. Chiricozzi, B. Pappalardi, V. Chigorno, N. Di Muzio, N. Loberto, S. Sonnino Published in Glycoconj J, DOI 10.1007/s10719-012-9385-2, 12/05/2012

• In vivo rectal wall measurements during HDR prostate brachytherapy with MOSkin dosimeters integrated on a trans-rectal US probe: Comparison with planned and reconstructed doses. Authors: M. Carrara, C. Tenconi, G. Rossi, M. Borroni, A. Cerrotta, S. Grisotto, D. Cusumano, B. Pappalardi, D. Cutajar, M. Petasecca, M. Lerch, G. Gambarini, C. Fallai, A. Rosenfeld, E. Pignoli Published in Radiotherapy and Oncology, 02/01/2016

• Comparison of different treatment planning optimization methods for vaginal HDR brachytherapy with multichannel applicators: A reduction of the high doses to the vaginal mucosa is possible. Authors: M. Carrara, D. Cusumano, T. Giandini, C. Tenconi, E. Mazzarella, S. Grisotto, E. Massari, D. Mazzeo, A. Cerrotta, B. Pappalardi, C. Fallai, E. Pignoli Published in Physica Medica, Volume 44, Pages 58-65, December 2017

Locally Advanced Cervical Cancer: Is a Trimodality Treatment a Safe and Effective Approach? Authors: D. Lorusso, F. Martinelli, G. Maltese, C. Fontanella, I. Sabatucci, A. Ditto, M. Signorelli, G. Bogani, S. Lepori, E. Tripodi, B. Pappalardi, C. Scaffa, A. Cerrotta, F. Raspagliesi Published in Oncology, 19/06/2018

• Pre-implant magnetic resonance and transrectal ultrasound imaging in high-dose-rate prostate brachytherapy: Comparison of prostate volumes, craniocaudal extents, and contours. Authors: S. Grisotto, A. Cerrotta, B. Pappalardi, M. Carrara, A. Messina, C. Tenconi, R. Valdagni, C. Fallai Published in J Contemp Brachytherapy, 31/08/2018

• Combination of Immunotherapy and Brain Radiotherapy in Metastatic Melanoma: A Retrospective Analysis Authors: G. Galli, S. Cavalieri, L. Di Guardo, C. Cimminiello, F. Nichetti, F. Corti, M.A. Garcia, B. Pappalardi, C. Fallai, F. de Braud, M. Platania, M. Del Vecchio Published in Oncol Res Treat, 2019; 42(4):186-194. doi: 10.1159/000497211. Published online on 05 March 2019

• An innovative gynecological HDR brachytherapy applicator system for treatment delivery and real-time verification Authors: A. Romanyukha, M. Carrara, D. Mazzeo, C. Tenconi, T. Al-Salmani, J. Poder, D. Cutajar, I. Fuduli, M. Petasecca, J. Bucci, A. Cerrotta, B. Pappalardi, F. Piccolo, E. Pignoli, A. Rosenfeld Published in Phys Med, March 2019; 59:151-157. doi: 10.1016/j.ejmp.2019.03.001. Published online on 07 March 2019

• High-dose-rate brachytherapy for high-grade vaginal intraepithelial neoplasia: A dosimetric analysis Authors: A. Barcellini, M. Lecchi, C. Tenconi, A. Macciotta, E. Pignoli, B. Pappalardi, E. Mazzarella, M. Carrara, T. Giandini, C. Fallai, P. Verderio, A. Cerrotta Published in J Contemp Brachytherapy, April 2019; 11(2):146-151. doi: 10.5114/jcb.2019.84696. Published online on 29 April 2019

Intraluminal Brachytherapy in Unresectable Extrahepatic Biliary Duct Cancer: An Italian Pooled Analysis Authors: R. Autorino, S. Bisiello, B. Pappalardi, et al. Published in Anticancer Res, 2020; 40(6):3417-3421. doi: 10.21873/anticanres.14326

• Cervical cancer patterns of care in Italy: A radiation oncology survey of MITO and AIRO GYN groups Authors: G. Macchia, A. Cerrotta, F. Deodato, B. Pappalardi, et al. Published in Crit Rev Oncol Hematol, 2020; 149:102925. doi: 10.1016/j.critrevonc.2020.102925

• Observational multicenter Italian study on vulvar cancer adjuvant radiotherapy (OLDLADY 1.2): A cooperation among AIRO Gyn, MITO and MaNGO groups Authors: G. Macchia, C. Casà, M. Ferioli, V. Lancellotta, D. Pezzulla, B. Pappalardi, et al. Published in Radiol Med, November 2022; 127(11):1292-1302

• Definitive chemoradiation in vulvar squamous cell carcinoma: Outcome and toxicity from an observational multicenter Italian study on vulvar cancer (OLDLADY 1.1) Authors: G. Macchia, V. Lancellotta, M. Ferioli, C. Casà, D. Pezzulla, B. Pappalardi, et al. Published in Radiol Med, September 2023; 129:152–159

Prevention and management of radiotherapy-related toxicities in gynecological malignancies. Position paper on behalf of AIRO (Italian Association of Radiotherapy and Clinical Oncology) Authors: Perrucci, Macchia, Cerrotta, Andrulli, Autorino, Barcellini, Campitelli, Corrao, Costantini, De Sanctis, Di Muzio, Epifani, Ferrazza, Fodor, Garibaldi, Laliscia, Lazzari, Magri, Mariucci, Pace, Pappalardi, et al. Published in Radiol Med, September 2024; 129(9):1329-1332

• 01/02/2021 – PRESENT Phase III randomized, double-blind clinical trial comparing chemoradiotherapy + Pembrolizumab (MK-3475) versus chemoradiotherapy in subjects with high-risk locally advanced cervical cancer (KEYNOTE-A18 / ENGOT-cx11 / GOG-3047). Role: Principal investigator for site 0542 (Fondazione IRCCS Istituto Nazionale dei Tumori) for external beam radiotherapy and brachytherapy treatments; Sub-investigator for site 0539 (Ospedale San Raffaele) for brachytherapy treatments.

• 01/08/2021 – PRESENT Phase III randomized, double-blind clinical trial comparing Pembrolizumab versus adjuvant chemotherapy +/- radiotherapy in high-risk endometrial cancer diagnoses after curative surgery (KEYNOTE-B21 / ENGOT-en11 / GOG-3053). Role: Sub-investigator for site 2122 (Fondazione IRCCS Istituto Nazionale dei Tumori) for external beam radiotherapy and brachytherapy treatments; Sub-investigator for site 2130 (Ospedale San Raffaele) for brachytherapy treatments.

• Embrace II Image-guided intensity-modulated external beam radiochemotherapy and MRI-based adaptive brachytherapy in locally advanced cervical cancer.